nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepenzolate—CHRM3—ureter—prostate cancer	0.0998	0.625	CbGeAlD
Mepenzolate—CHRM2—prostate gland—prostate cancer	0.0143	0.0895	CbGeAlD
Mepenzolate—CHRM1—prostate gland—prostate cancer	0.013	0.0815	CbGeAlD
Mepenzolate—CHRM3—prostate gland—prostate cancer	0.0116	0.0729	CbGeAlD
Mepenzolate—Cyclizine—SULT1E1—prostate cancer	0.00927	0.438	CrCbGaD
Mepenzolate—CHRM3—renal system—prostate cancer	0.00793	0.0497	CbGeAlD
Mepenzolate—CHRM3—urethra—prostate cancer	0.00779	0.0488	CbGeAlD
Mepenzolate—CHRM3—testis—prostate cancer	0.00513	0.0321	CbGeAlD
Mepenzolate—Ageusia—Capecitabine—prostate cancer	0.00385	0.00592	CcSEcCtD
Mepenzolate—Dry mouth—Cabazitaxel—prostate cancer	0.00385	0.00592	CcSEcCtD
Mepenzolate—Urticaria—Estrone—prostate cancer	0.00384	0.0059	CcSEcCtD
Mepenzolate—Constipation—Nilutamide—prostate cancer	0.00384	0.0059	CcSEcCtD
Mepenzolate—Constipation—Flutamide—prostate cancer	0.00382	0.00587	CcSEcCtD
Mepenzolate—Confusional state—Cabazitaxel—prostate cancer	0.00381	0.00585	CcSEcCtD
Mepenzolate—Feeling abnormal—Nilutamide—prostate cancer	0.0037	0.00568	CcSEcCtD
Mepenzolate—Tachycardia—Cabazitaxel—prostate cancer	0.00369	0.00566	CcSEcCtD
Mepenzolate—Feeling abnormal—Flutamide—prostate cancer	0.00368	0.00566	CcSEcCtD
Mepenzolate—Erectile dysfunction—Goserelin—prostate cancer	0.00365	0.00561	CcSEcCtD
Mepenzolate—Insomnia—Degarelix—prostate cancer	0.00363	0.00557	CcSEcCtD
Mepenzolate—Drowsiness—Goserelin—prostate cancer	0.00353	0.00543	CcSEcCtD
Mepenzolate—Asthenia—Abiraterone—prostate cancer	0.00352	0.00542	CcSEcCtD
Mepenzolate—Constipation—Degarelix—prostate cancer	0.00343	0.00527	CcSEcCtD
Mepenzolate—Urticaria—Estradiol valerate/Dienogest—prostate cancer	0.00335	0.00515	CcSEcCtD
Mepenzolate—Dry mouth—Bicalutamide—prostate cancer	0.00331	0.00508	CcSEcCtD
Mepenzolate—Feeling abnormal—Degarelix—prostate cancer	0.0033	0.00508	CcSEcCtD
Mepenzolate—Confusional state—Bicalutamide—prostate cancer	0.00327	0.00502	CcSEcCtD
Mepenzolate—Constipation—Cabazitaxel—prostate cancer	0.00323	0.00496	CcSEcCtD
Mepenzolate—Asthenia—Nilutamide—prostate cancer	0.00322	0.00495	CcSEcCtD
Mepenzolate—Vomiting—Estramustine—prostate cancer	0.00322	0.00494	CcSEcCtD
Mepenzolate—Asthenia—Flutamide—prostate cancer	0.00321	0.00493	CcSEcCtD
Mepenzolate—Dizziness—Estrone—prostate cancer	0.0032	0.00491	CcSEcCtD
Mepenzolate—Urticaria—Degarelix—prostate cancer	0.00318	0.00489	CcSEcCtD
Mepenzolate—Headache—Estramustine—prostate cancer	0.00317	0.00487	CcSEcCtD
Mepenzolate—Abdominal distension—Estradiol—prostate cancer	0.00316	0.00486	CcSEcCtD
Mepenzolate—Vomiting—Abiraterone—prostate cancer	0.00312	0.0048	CcSEcCtD
Mepenzolate—Feeling abnormal—Cabazitaxel—prostate cancer	0.00311	0.00478	CcSEcCtD
Mepenzolate—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.00311	0.00477	CcSEcCtD
Mepenzolate—Vomiting—Estrone—prostate cancer	0.00307	0.00472	CcSEcCtD
Mepenzolate—Headache—Estrone—prostate cancer	0.00303	0.00465	CcSEcCtD
Mepenzolate—Asthenia—Estradiol valerate/Dienogest—prostate cancer	0.00303	0.00465	CcSEcCtD
Mepenzolate—Nausea—Estramustine—prostate cancer	0.003	0.00462	CcSEcCtD
Mepenzolate—Dizziness—Nilutamide—prostate cancer	0.00297	0.00456	CcSEcCtD
Mepenzolate—Dizziness—Flutamide—prostate cancer	0.00295	0.00454	CcSEcCtD
Mepenzolate—Hypersensitivity—Degarelix—prostate cancer	0.00295	0.00454	CcSEcCtD
Mepenzolate—Insomnia—Bicalutamide—prostate cancer	0.00293	0.0045	CcSEcCtD
Mepenzolate—Somnolence—Bicalutamide—prostate cancer	0.00288	0.00443	CcSEcCtD
Mepenzolate—Asthenia—Degarelix—prostate cancer	0.00288	0.00442	CcSEcCtD
Mepenzolate—Nausea—Estrone—prostate cancer	0.00287	0.00441	CcSEcCtD
Mepenzolate—Vomiting—Nilutamide—prostate cancer	0.00285	0.00438	CcSEcCtD
Mepenzolate—Vomiting—Flutamide—prostate cancer	0.00284	0.00437	CcSEcCtD
Mepenzolate—Headache—Nilutamide—prostate cancer	0.00281	0.00432	CcSEcCtD
Mepenzolate—Headache—Flutamide—prostate cancer	0.0028	0.0043	CcSEcCtD
Mepenzolate—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00279	0.00429	CcSEcCtD
Mepenzolate—Hypersensitivity—Cabazitaxel—prostate cancer	0.00278	0.00428	CcSEcCtD
Mepenzolate—Constipation—Bicalutamide—prostate cancer	0.00277	0.00426	CcSEcCtD
Mepenzolate—Tension—Goserelin—prostate cancer	0.00271	0.00416	CcSEcCtD
Mepenzolate—Asthenia—Cabazitaxel—prostate cancer	0.00271	0.00416	CcSEcCtD
Mepenzolate—Erectile dysfunction—Mitoxantrone—prostate cancer	0.0027	0.00414	CcSEcCtD
Mepenzolate—Ageusia—Epirubicin—prostate cancer	0.00269	0.00413	CcSEcCtD
Mepenzolate—Tension—Conjugated Estrogens—prostate cancer	0.00268	0.00412	CcSEcCtD
Mepenzolate—Nervousness—Goserelin—prostate cancer	0.00268	0.00412	CcSEcCtD
Mepenzolate—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00268	0.00412	CcSEcCtD
Mepenzolate—Feeling abnormal—Bicalutamide—prostate cancer	0.00267	0.0041	CcSEcCtD
Mepenzolate—Nausea—Nilutamide—prostate cancer	0.00267	0.0041	CcSEcCtD
Mepenzolate—Nervousness—Conjugated Estrogens—prostate cancer	0.00266	0.00408	CcSEcCtD
Mepenzolate—Nausea—Flutamide—prostate cancer	0.00265	0.00408	CcSEcCtD
Mepenzolate—Dizziness—Degarelix—prostate cancer	0.00265	0.00407	CcSEcCtD
Mepenzolate—Headache—Estradiol valerate/Dienogest—prostate cancer	0.00264	0.00406	CcSEcCtD
Mepenzolate—Drowsiness—Mitoxantrone—prostate cancer	0.00261	0.00401	CcSEcCtD
Mepenzolate—Vision blurred—Goserelin—prostate cancer	0.0026	0.004	CcSEcCtD
Mepenzolate—Vision blurred—Conjugated Estrogens—prostate cancer	0.00258	0.00396	CcSEcCtD
Mepenzolate—Urticaria—Bicalutamide—prostate cancer	0.00257	0.00396	CcSEcCtD
Mepenzolate—Vomiting—Degarelix—prostate cancer	0.00255	0.00392	CcSEcCtD
Mepenzolate—Headache—Degarelix—prostate cancer	0.00251	0.00386	CcSEcCtD
Mepenzolate—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.0025	0.00385	CcSEcCtD
Mepenzolate—Dizziness—Cabazitaxel—prostate cancer	0.0025	0.00384	CcSEcCtD
Mepenzolate—Ageusia—Doxorubicin—prostate cancer	0.00248	0.00382	CcSEcCtD
Mepenzolate—Palpitations—Goserelin—prostate cancer	0.00244	0.00375	CcSEcCtD
Mepenzolate—Palpitations—Conjugated Estrogens—prostate cancer	0.00242	0.00371	CcSEcCtD
Mepenzolate—Vomiting—Cabazitaxel—prostate cancer	0.0024	0.00369	CcSEcCtD
Mepenzolate—Hypersensitivity—Bicalutamide—prostate cancer	0.00239	0.00367	CcSEcCtD
Mepenzolate—Nausea—Degarelix—prostate cancer	0.00238	0.00366	CcSEcCtD
Mepenzolate—Headache—Cabazitaxel—prostate cancer	0.00237	0.00364	CcSEcCtD
Mepenzolate—Constipation—Ethinyl Estradiol—prostate cancer	0.00234	0.0036	CcSEcCtD
Mepenzolate—Asthenia—Bicalutamide—prostate cancer	0.00232	0.00357	CcSEcCtD
Mepenzolate—Dry mouth—Goserelin—prostate cancer	0.0023	0.00353	CcSEcCtD
Mepenzolate—Confusional state—Goserelin—prostate cancer	0.00227	0.00349	CcSEcCtD
Mepenzolate—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.00226	0.00347	CcSEcCtD
Mepenzolate—Anaphylactic shock—Goserelin—prostate cancer	0.00225	0.00346	CcSEcCtD
Mepenzolate—Nausea—Cabazitaxel—prostate cancer	0.00224	0.00345	CcSEcCtD
Mepenzolate—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.00223	0.00343	CcSEcCtD
Mepenzolate—Tachycardia—Goserelin—prostate cancer	0.0022	0.00338	CcSEcCtD
Mepenzolate—Tachycardia—Conjugated Estrogens—prostate cancer	0.00218	0.00335	CcSEcCtD
Mepenzolate—Urticaria—Ethinyl Estradiol—prostate cancer	0.00218	0.00334	CcSEcCtD
Mepenzolate—Urinary retention—Capecitabine—prostate cancer	0.00216	0.00331	CcSEcCtD
Mepenzolate—Tension—Estradiol—prostate cancer	0.00215	0.0033	CcSEcCtD
Mepenzolate—Dizziness—Bicalutamide—prostate cancer	0.00214	0.00329	CcSEcCtD
Mepenzolate—Nervousness—Estradiol—prostate cancer	0.00213	0.00327	CcSEcCtD
Mepenzolate—Vomiting—Bicalutamide—prostate cancer	0.00206	0.00317	CcSEcCtD
Mepenzolate—Insomnia—Goserelin—prostate cancer	0.00204	0.00313	CcSEcCtD
Mepenzolate—Headache—Bicalutamide—prostate cancer	0.00203	0.00312	CcSEcCtD
Mepenzolate—Insomnia—Conjugated Estrogens—prostate cancer	0.00202	0.0031	CcSEcCtD
Mepenzolate—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00202	0.0031	CcSEcCtD
Mepenzolate—Somnolence—Goserelin—prostate cancer	0.002	0.00308	CcSEcCtD
Mepenzolate—Somnolence—Conjugated Estrogens—prostate cancer	0.00198	0.00305	CcSEcCtD
Mepenzolate—Abdominal distension—Capecitabine—prostate cancer	0.00197	0.00303	CcSEcCtD
Mepenzolate—Asthenia—Ethinyl Estradiol—prostate cancer	0.00196	0.00302	CcSEcCtD
Mepenzolate—Palpitations—Estradiol—prostate cancer	0.00193	0.00297	CcSEcCtD
Mepenzolate—Constipation—Goserelin—prostate cancer	0.00193	0.00296	CcSEcCtD
Mepenzolate—Nausea—Bicalutamide—prostate cancer	0.00192	0.00296	CcSEcCtD
Mepenzolate—Vision blurred—Mitoxantrone—prostate cancer	0.00192	0.00295	CcSEcCtD
Mepenzolate—Constipation—Conjugated Estrogens—prostate cancer	0.00191	0.00293	CcSEcCtD
Mepenzolate—Feeling abnormal—Goserelin—prostate cancer	0.00186	0.00285	CcSEcCtD
Mepenzolate—Dry mouth—Estradiol—prostate cancer	0.00182	0.0028	CcSEcCtD
Mepenzolate—Dizziness—Ethinyl Estradiol—prostate cancer	0.00181	0.00278	CcSEcCtD
Mepenzolate—Confusional state—Estradiol—prostate cancer	0.0018	0.00277	CcSEcCtD
Mepenzolate—Urticaria—Goserelin—prostate cancer	0.00179	0.00275	CcSEcCtD
Mepenzolate—Anaphylactic shock—Estradiol—prostate cancer	0.00179	0.00275	CcSEcCtD
Mepenzolate—Urticaria—Conjugated Estrogens—prostate cancer	0.00177	0.00273	CcSEcCtD
Mepenzolate—Abdominal distension—Prednisone—prostate cancer	0.00176	0.0027	CcSEcCtD
Mepenzolate—Tachycardia—Estradiol—prostate cancer	0.00174	0.00268	CcSEcCtD
Mepenzolate—Vomiting—Ethinyl Estradiol—prostate cancer	0.00174	0.00268	CcSEcCtD
Mepenzolate—Headache—Ethinyl Estradiol—prostate cancer	0.00172	0.00264	CcSEcCtD
Mepenzolate—Confusional state—Mitoxantrone—prostate cancer	0.00168	0.00258	CcSEcCtD
Mepenzolate—Anaphylactic shock—Mitoxantrone—prostate cancer	0.00166	0.00256	CcSEcCtD
Mepenzolate—Hypersensitivity—Goserelin—prostate cancer	0.00166	0.00255	CcSEcCtD
Mepenzolate—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.00164	0.00253	CcSEcCtD
Mepenzolate—Nausea—Ethinyl Estradiol—prostate cancer	0.00163	0.0025	CcSEcCtD
Mepenzolate—Tachycardia—Mitoxantrone—prostate cancer	0.00162	0.0025	CcSEcCtD
Mepenzolate—Asthenia—Goserelin—prostate cancer	0.00162	0.00248	CcSEcCtD
Mepenzolate—Insomnia—Estradiol—prostate cancer	0.00162	0.00248	CcSEcCtD
Mepenzolate—Erectile dysfunction—Prednisone—prostate cancer	0.00161	0.00247	CcSEcCtD
Mepenzolate—Asthenia—Conjugated Estrogens—prostate cancer	0.0016	0.00246	CcSEcCtD
Mepenzolate—Somnolence—Estradiol—prostate cancer	0.00159	0.00244	CcSEcCtD
Mepenzolate—Constipation—Estradiol—prostate cancer	0.00153	0.00235	CcSEcCtD
Mepenzolate—Dizziness—Goserelin—prostate cancer	0.00149	0.00229	CcSEcCtD
Mepenzolate—Somnolence—Mitoxantrone—prostate cancer	0.00148	0.00227	CcSEcCtD
Mepenzolate—Dizziness—Conjugated Estrogens—prostate cancer	0.00148	0.00227	CcSEcCtD
Mepenzolate—Feeling abnormal—Estradiol—prostate cancer	0.00147	0.00226	CcSEcCtD
Mepenzolate—Vomiting—Goserelin—prostate cancer	0.00143	0.0022	CcSEcCtD
Mepenzolate—Constipation—Mitoxantrone—prostate cancer	0.00142	0.00219	CcSEcCtD
Mepenzolate—Vomiting—Conjugated Estrogens—prostate cancer	0.00142	0.00218	CcSEcCtD
Mepenzolate—Urticaria—Estradiol—prostate cancer	0.00142	0.00218	CcSEcCtD
Mepenzolate—Headache—Goserelin—prostate cancer	0.00141	0.00217	CcSEcCtD
Mepenzolate—Headache—Conjugated Estrogens—prostate cancer	0.0014	0.00215	CcSEcCtD
Mepenzolate—Confusional state—Etoposide—prostate cancer	0.0014	0.00215	CcSEcCtD
Mepenzolate—Anaphylactic shock—Etoposide—prostate cancer	0.00138	0.00213	CcSEcCtD
Mepenzolate—Abdominal distension—Epirubicin—prostate cancer	0.00137	0.00211	CcSEcCtD
Mepenzolate—Feeling abnormal—Mitoxantrone—prostate cancer	0.00137	0.00211	CcSEcCtD
Mepenzolate—Tachycardia—Etoposide—prostate cancer	0.00135	0.00208	CcSEcCtD
Mepenzolate—Nausea—Goserelin—prostate cancer	0.00134	0.00206	CcSEcCtD
Mepenzolate—Nausea—Conjugated Estrogens—prostate cancer	0.00133	0.00204	CcSEcCtD
Mepenzolate—Urticaria—Mitoxantrone—prostate cancer	0.00132	0.00203	CcSEcCtD
Mepenzolate—Hypersensitivity—Estradiol—prostate cancer	0.00132	0.00202	CcSEcCtD
Mepenzolate—Levomethadyl Acetate—CYP3A5—prostate cancer	0.0013	0.0614	CrCbGaD
Mepenzolate—Vision blurred—Capecitabine—prostate cancer	0.00129	0.00198	CcSEcCtD
Mepenzolate—Asthenia—Estradiol—prostate cancer	0.00128	0.00197	CcSEcCtD
Mepenzolate—Abdominal distension—Doxorubicin—prostate cancer	0.00127	0.00195	CcSEcCtD
Mepenzolate—Palpitations—Docetaxel—prostate cancer	0.00125	0.00191	CcSEcCtD
Mepenzolate—Somnolence—Etoposide—prostate cancer	0.00123	0.00189	CcSEcCtD
Mepenzolate—Hypersensitivity—Mitoxantrone—prostate cancer	0.00123	0.00188	CcSEcCtD
Mepenzolate—Drowsiness—Epirubicin—prostate cancer	0.00122	0.00187	CcSEcCtD
Mepenzolate—Palpitations—Capecitabine—prostate cancer	0.00121	0.00185	CcSEcCtD
Mepenzolate—Levomethadyl Acetate—CYP19A1—prostate cancer	0.0012	0.0565	CrCbGaD
Mepenzolate—Asthenia—Mitoxantrone—prostate cancer	0.00119	0.00184	CcSEcCtD
Mepenzolate—Constipation—Etoposide—prostate cancer	0.00118	0.00182	CcSEcCtD
Mepenzolate—Dizziness—Estradiol—prostate cancer	0.00118	0.00182	CcSEcCtD
Mepenzolate—Dry mouth—Docetaxel—prostate cancer	0.00117	0.0018	CcSEcCtD
Mepenzolate—Confusional state—Docetaxel—prostate cancer	0.00116	0.00178	CcSEcCtD
Mepenzolate—Methadone—CYP2C18—prostate cancer	0.00116	0.0546	CrCbGaD
Mepenzolate—Anaphylactic shock—Docetaxel—prostate cancer	0.00115	0.00177	CcSEcCtD
Mepenzolate—Vision blurred—Prednisone—prostate cancer	0.00115	0.00176	CcSEcCtD
Mepenzolate—Feeling abnormal—Etoposide—prostate cancer	0.00114	0.00175	CcSEcCtD
Mepenzolate—Dry mouth—Capecitabine—prostate cancer	0.00114	0.00175	CcSEcCtD
Mepenzolate—Vomiting—Estradiol—prostate cancer	0.00114	0.00175	CcSEcCtD
Mepenzolate—Drowsiness—Doxorubicin—prostate cancer	0.00113	0.00173	CcSEcCtD
Mepenzolate—Confusional state—Capecitabine—prostate cancer	0.00112	0.00173	CcSEcCtD
Mepenzolate—Tachycardia—Docetaxel—prostate cancer	0.00112	0.00173	CcSEcCtD
Mepenzolate—Headache—Estradiol—prostate cancer	0.00112	0.00172	CcSEcCtD
Mepenzolate—Fentanyl—CYP3A5—prostate cancer	0.00111	0.0524	CrCbGaD
Mepenzolate—Urticaria—Etoposide—prostate cancer	0.0011	0.00169	CcSEcCtD
Mepenzolate—Tachycardia—Capecitabine—prostate cancer	0.00109	0.00167	CcSEcCtD
Mepenzolate—Nausea—Estradiol—prostate cancer	0.00106	0.00163	CcSEcCtD
Mepenzolate—Vomiting—Mitoxantrone—prostate cancer	0.00106	0.00163	CcSEcCtD
Mepenzolate—Clemastine—CYP3A4—prostate cancer	0.00105	0.0496	CrCbGaD
Mepenzolate—Benzatropine—CYP2C19—prostate cancer	0.00104	0.0493	CrCbGaD
Mepenzolate—Headache—Mitoxantrone—prostate cancer	0.00104	0.0016	CcSEcCtD
Mepenzolate—Insomnia—Docetaxel—prostate cancer	0.00104	0.0016	CcSEcCtD
Mepenzolate—Somnolence—Docetaxel—prostate cancer	0.00102	0.00157	CcSEcCtD
Mepenzolate—Hypersensitivity—Etoposide—prostate cancer	0.00102	0.00157	CcSEcCtD
Mepenzolate—Insomnia—Capecitabine—prostate cancer	0.00101	0.00155	CcSEcCtD
Mepenzolate—Asthenia—Etoposide—prostate cancer	0.000993	0.00153	CcSEcCtD
Mepenzolate—Anaphylactic shock—Prednisone—prostate cancer	0.000992	0.00153	CcSEcCtD
Mepenzolate—Nausea—Mitoxantrone—prostate cancer	0.000989	0.00152	CcSEcCtD
Mepenzolate—Constipation—Docetaxel—prostate cancer	0.000984	0.00151	CcSEcCtD
Mepenzolate—Tachycardia—Prednisone—prostate cancer	0.000969	0.00149	CcSEcCtD
Mepenzolate—Constipation—Capecitabine—prostate cancer	0.000953	0.00146	CcSEcCtD
Mepenzolate—Feeling abnormal—Docetaxel—prostate cancer	0.000948	0.00146	CcSEcCtD
Mepenzolate—Tension—Epirubicin—prostate cancer	0.000933	0.00143	CcSEcCtD
Mepenzolate—Nervousness—Epirubicin—prostate cancer	0.000924	0.00142	CcSEcCtD
Mepenzolate—Feeling abnormal—Capecitabine—prostate cancer	0.000918	0.00141	CcSEcCtD
Mepenzolate—Dizziness—Etoposide—prostate cancer	0.000916	0.00141	CcSEcCtD
Mepenzolate—Insomnia—Prednisone—prostate cancer	0.000898	0.00138	CcSEcCtD
Mepenzolate—Vision blurred—Epirubicin—prostate cancer	0.000896	0.00138	CcSEcCtD
Mepenzolate—Urticaria—Capecitabine—prostate cancer	0.000885	0.00136	CcSEcCtD
Mepenzolate—Vomiting—Etoposide—prostate cancer	0.00088	0.00135	CcSEcCtD
Mepenzolate—Headache—Etoposide—prostate cancer	0.000867	0.00133	CcSEcCtD
Mepenzolate—Tension—Doxorubicin—prostate cancer	0.000864	0.00133	CcSEcCtD
Mepenzolate—Nervousness—Doxorubicin—prostate cancer	0.000855	0.00131	CcSEcCtD
Mepenzolate—Constipation—Prednisone—prostate cancer	0.000849	0.0013	CcSEcCtD
Mepenzolate—Hypersensitivity—Docetaxel—prostate cancer	0.000848	0.0013	CcSEcCtD
Mepenzolate—Palpitations—Epirubicin—prostate cancer	0.00084	0.00129	CcSEcCtD
Mepenzolate—Vision blurred—Doxorubicin—prostate cancer	0.000829	0.00127	CcSEcCtD
Mepenzolate—Asthenia—Docetaxel—prostate cancer	0.000826	0.00127	CcSEcCtD
Mepenzolate—Nausea—Etoposide—prostate cancer	0.000822	0.00126	CcSEcCtD
Mepenzolate—Hypersensitivity—Capecitabine—prostate cancer	0.000821	0.00126	CcSEcCtD
Mepenzolate—Feeling abnormal—Prednisone—prostate cancer	0.000818	0.00126	CcSEcCtD
Mepenzolate—Asthenia—Capecitabine—prostate cancer	0.000799	0.00123	CcSEcCtD
Mepenzolate—Dry mouth—Epirubicin—prostate cancer	0.000792	0.00122	CcSEcCtD
Mepenzolate—Urticaria—Prednisone—prostate cancer	0.000788	0.00121	CcSEcCtD
Mepenzolate—Confusional state—Epirubicin—prostate cancer	0.000783	0.0012	CcSEcCtD
Mepenzolate—Palpitations—Doxorubicin—prostate cancer	0.000778	0.0012	CcSEcCtD
Mepenzolate—Anaphylactic shock—Epirubicin—prostate cancer	0.000776	0.00119	CcSEcCtD
Mepenzolate—Methadone—CYP3A5—prostate cancer	0.000762	0.036	CrCbGaD
Mepenzolate—Dizziness—Docetaxel—prostate cancer	0.000761	0.00117	CcSEcCtD
Mepenzolate—Tachycardia—Epirubicin—prostate cancer	0.000758	0.00116	CcSEcCtD
Mepenzolate—Darifenacin—CYP3A4—prostate cancer	0.000748	0.0353	CrCbGaD
Mepenzolate—Dizziness—Capecitabine—prostate cancer	0.000737	0.00113	CcSEcCtD
Mepenzolate—Dry mouth—Doxorubicin—prostate cancer	0.000733	0.00113	CcSEcCtD
Mepenzolate—Vomiting—Docetaxel—prostate cancer	0.000732	0.00112	CcSEcCtD
Mepenzolate—Hypersensitivity—Prednisone—prostate cancer	0.000731	0.00112	CcSEcCtD
Mepenzolate—Confusional state—Doxorubicin—prostate cancer	0.000724	0.00111	CcSEcCtD
Mepenzolate—Headache—Docetaxel—prostate cancer	0.000721	0.00111	CcSEcCtD
Mepenzolate—Anaphylactic shock—Doxorubicin—prostate cancer	0.000718	0.0011	CcSEcCtD
Mepenzolate—Asthenia—Prednisone—prostate cancer	0.000712	0.00109	CcSEcCtD
Mepenzolate—Vomiting—Capecitabine—prostate cancer	0.000708	0.00109	CcSEcCtD
Mepenzolate—Insomnia—Epirubicin—prostate cancer	0.000702	0.00108	CcSEcCtD
Mepenzolate—Methadone—CYP19A1—prostate cancer	0.000702	0.0331	CrCbGaD
Mepenzolate—Tachycardia—Doxorubicin—prostate cancer	0.000701	0.00108	CcSEcCtD
Mepenzolate—Headache—Capecitabine—prostate cancer	0.000698	0.00107	CcSEcCtD
Mepenzolate—Somnolence—Epirubicin—prostate cancer	0.00069	0.00106	CcSEcCtD
Mepenzolate—Nausea—Docetaxel—prostate cancer	0.000684	0.00105	CcSEcCtD
Mepenzolate—Constipation—Epirubicin—prostate cancer	0.000664	0.00102	CcSEcCtD
Mepenzolate—Nausea—Capecitabine—prostate cancer	0.000662	0.00102	CcSEcCtD
Mepenzolate—Dizziness—Prednisone—prostate cancer	0.000656	0.00101	CcSEcCtD
Mepenzolate—Insomnia—Doxorubicin—prostate cancer	0.00065	0.000998	CcSEcCtD
Mepenzolate—Feeling abnormal—Epirubicin—prostate cancer	0.00064	0.000983	CcSEcCtD
Mepenzolate—Somnolence—Doxorubicin—prostate cancer	0.000638	0.000981	CcSEcCtD
Mepenzolate—Vomiting—Prednisone—prostate cancer	0.000631	0.00097	CcSEcCtD
Mepenzolate—Headache—Prednisone—prostate cancer	0.000622	0.000955	CcSEcCtD
Mepenzolate—Urticaria—Epirubicin—prostate cancer	0.000617	0.000948	CcSEcCtD
Mepenzolate—Constipation—Doxorubicin—prostate cancer	0.000614	0.000944	CcSEcCtD
Mepenzolate—Feeling abnormal—Doxorubicin—prostate cancer	0.000592	0.000909	CcSEcCtD
Mepenzolate—Nausea—Prednisone—prostate cancer	0.000589	0.000906	CcSEcCtD
Mepenzolate—Hypersensitivity—Epirubicin—prostate cancer	0.000572	0.000879	CcSEcCtD
Mepenzolate—Urticaria—Doxorubicin—prostate cancer	0.000571	0.000877	CcSEcCtD
Mepenzolate—Levomethadyl Acetate—CYP3A4—prostate cancer	0.000562	0.0266	CrCbGaD
Mepenzolate—Asthenia—Epirubicin—prostate cancer	0.000557	0.000856	CcSEcCtD
Mepenzolate—Hypersensitivity—Doxorubicin—prostate cancer	0.000529	0.000813	CcSEcCtD
Mepenzolate—Methadone—CYP2C19—prostate cancer	0.000518	0.0245	CrCbGaD
Mepenzolate—Asthenia—Doxorubicin—prostate cancer	0.000515	0.000792	CcSEcCtD
Mepenzolate—Dizziness—Epirubicin—prostate cancer	0.000513	0.000789	CcSEcCtD
Mepenzolate—Vomiting—Epirubicin—prostate cancer	0.000494	0.000758	CcSEcCtD
Mepenzolate—Headache—Epirubicin—prostate cancer	0.000486	0.000747	CcSEcCtD
Mepenzolate—Dextropropoxyphene—CYP3A4—prostate cancer	0.000486	0.023	CrCbGaD
Mepenzolate—Fentanyl—CYP3A4—prostate cancer	0.000481	0.0227	CrCbGaD
Mepenzolate—Dizziness—Doxorubicin—prostate cancer	0.000475	0.00073	CcSEcCtD
Mepenzolate—Loperamide—CYP3A4—prostate cancer	0.000463	0.0219	CrCbGaD
Mepenzolate—Nausea—Epirubicin—prostate cancer	0.000461	0.000709	CcSEcCtD
Mepenzolate—Vomiting—Doxorubicin—prostate cancer	0.000457	0.000702	CcSEcCtD
Mepenzolate—Headache—Doxorubicin—prostate cancer	0.00045	0.000691	CcSEcCtD
Mepenzolate—Nausea—Doxorubicin—prostate cancer	0.000427	0.000656	CcSEcCtD
Mepenzolate—Methadone—CYP3A4—prostate cancer	0.00033	0.0156	CrCbGaD
Mepenzolate—CHRM1—GPCR downstream signaling—PIK3CD—prostate cancer	4.71e-05	0.00028	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—PIK3CD—prostate cancer	4.7e-05	0.000279	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—TYMS—prostate cancer	4.67e-05	0.000277	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PRKCQ—prostate cancer	4.66e-05	0.000277	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NGFR—prostate cancer	4.66e-05	0.000277	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PIK3CD—prostate cancer	4.65e-05	0.000276	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NGFR—prostate cancer	4.65e-05	0.000276	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PRKCQ—prostate cancer	4.65e-05	0.000276	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—GSTM1—prostate cancer	4.62e-05	0.000274	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MAP3K7—prostate cancer	4.61e-05	0.000273	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NGFR—prostate cancer	4.6e-05	0.000273	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PRKCQ—prostate cancer	4.6e-05	0.000273	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MAP3K7—prostate cancer	4.59e-05	0.000273	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MAP3K7—prostate cancer	4.55e-05	0.00027	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—LPL—prostate cancer	4.53e-05	0.000269	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGF10—prostate cancer	4.43e-05	0.000263	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGF10—prostate cancer	4.42e-05	0.000262	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ADRB2—prostate cancer	4.38e-05	0.00026	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CYP1A1—prostate cancer	4.38e-05	0.00026	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGF10—prostate cancer	4.37e-05	0.00026	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ADRB2—prostate cancer	4.37e-05	0.000259	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—ERCC2—prostate cancer	4.34e-05	0.000258	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ADRB2—prostate cancer	4.33e-05	0.000257	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—JAK2—prostate cancer	4.32e-05	0.000257	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—JAK2—prostate cancer	4.31e-05	0.000256	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—MAP2K1—prostate cancer	4.31e-05	0.000256	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—MAP2K1—prostate cancer	4.29e-05	0.000255	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3CD—prostate cancer	4.28e-05	0.000254	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—VAV3—prostate cancer	4.28e-05	0.000254	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—JAK2—prostate cancer	4.27e-05	0.000253	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3CD—prostate cancer	4.27e-05	0.000253	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—VAV3—prostate cancer	4.26e-05	0.000253	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—MAP2K1—prostate cancer	4.25e-05	0.000252	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3CD—prostate cancer	4.22e-05	0.000251	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—VAV3—prostate cancer	4.22e-05	0.00025	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TGFBR2—prostate cancer	4.21e-05	0.00025	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TGFBR2—prostate cancer	4.2e-05	0.000249	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TGFBR2—prostate cancer	4.16e-05	0.000247	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ITPR1—prostate cancer	4.15e-05	0.000246	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ITPR1—prostate cancer	4.13e-05	0.000245	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—PIK3CB—prostate cancer	4.11e-05	0.000244	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—PIK3CB—prostate cancer	4.09e-05	0.000243	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ITPR1—prostate cancer	4.09e-05	0.000243	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—MTHFR—prostate cancer	4.08e-05	0.000242	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PIK3CB—prostate cancer	4.05e-05	0.000241	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PPARA—prostate cancer	4e-05	0.000238	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IGF1R—prostate cancer	3.97e-05	0.000235	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IGF1R—prostate cancer	3.95e-05	0.000235	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—CXCL8—prostate cancer	3.95e-05	0.000234	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—CXCL8—prostate cancer	3.93e-05	0.000233	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—JAK2—prostate cancer	3.93e-05	0.000233	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—JAK2—prostate cancer	3.91e-05	0.000232	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IGF1R—prostate cancer	3.91e-05	0.000232	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—CXCL8—prostate cancer	3.9e-05	0.000231	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—JAK2—prostate cancer	3.88e-05	0.00023	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—LPL—prostate cancer	3.8e-05	0.000226	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—LPL—prostate cancer	3.79e-05	0.000225	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—IL2—prostate cancer	3.77e-05	0.000224	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PDGFRB—prostate cancer	3.77e-05	0.000224	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CAV1—prostate cancer	3.76e-05	0.000223	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—IL2—prostate cancer	3.76e-05	0.000223	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PDGFRB—prostate cancer	3.76e-05	0.000223	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—LPL—prostate cancer	3.75e-05	0.000223	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3CB—prostate cancer	3.73e-05	0.000221	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—IL2—prostate cancer	3.72e-05	0.000221	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PDGFRB—prostate cancer	3.72e-05	0.000221	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3CB—prostate cancer	3.72e-05	0.000221	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3CB—prostate cancer	3.68e-05	0.000218	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ITGB3—prostate cancer	3.67e-05	0.000218	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ITGB3—prostate cancer	3.66e-05	0.000217	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ITGB3—prostate cancer	3.62e-05	0.000215	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—CXCL8—prostate cancer	3.58e-05	0.000213	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—CXCL8—prostate cancer	3.57e-05	0.000212	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ERBB3—prostate cancer	3.56e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGFR2—prostate cancer	3.56e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ERBB3—prostate cancer	3.55e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGFR2—prostate cancer	3.54e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	3.54e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ERBB3—prostate cancer	3.52e-05	0.000209	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGFR2—prostate cancer	3.51e-05	0.000208	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CG—prostate cancer	3.43e-05	0.000203	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—IL2—prostate cancer	3.43e-05	0.000203	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—IL2—prostate cancer	3.41e-05	0.000203	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TERT—prostate cancer	3.41e-05	0.000203	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TERT—prostate cancer	3.4e-05	0.000202	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—IL2—prostate cancer	3.38e-05	0.000201	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TERT—prostate cancer	3.37e-05	0.0002	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HIF1A—prostate cancer	3.26e-05	0.000194	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HIF1A—prostate cancer	3.25e-05	0.000193	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—INS—prostate cancer	3.25e-05	0.000193	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HIF1A—prostate cancer	3.22e-05	0.000191	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—LEP—prostate cancer	3.19e-05	0.000189	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CREBBP—prostate cancer	3.18e-05	0.000189	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—LEP—prostate cancer	3.18e-05	0.000188	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CAV1—prostate cancer	3.16e-05	0.000187	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CAV1—prostate cancer	3.15e-05	0.000187	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—LEP—prostate cancer	3.15e-05	0.000187	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—KDR—prostate cancer	3.12e-05	0.000185	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CAV1—prostate cancer	3.12e-05	0.000185	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—KDR—prostate cancer	3.11e-05	0.000185	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—KDR—prostate cancer	3.08e-05	0.000183	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ESR1—prostate cancer	3.04e-05	0.000181	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ESR1—prostate cancer	3.03e-05	0.00018	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CD—prostate cancer	3.01e-05	0.000179	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ESR1—prostate cancer	3e-05	0.000178	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—BAD—prostate cancer	2.97e-05	0.000176	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—BAD—prostate cancer	2.96e-05	0.000176	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—BAD—prostate cancer	2.93e-05	0.000174	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—APC—prostate cancer	2.88e-05	0.000171	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	2.88e-05	0.000171	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—APC—prostate cancer	2.87e-05	0.00017	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	2.87e-05	0.00017	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—NOS3—prostate cancer	2.85e-05	0.000169	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IRS1—prostate cancer	2.84e-05	0.000169	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EGF—prostate cancer	2.84e-05	0.000169	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	2.84e-05	0.000168	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—APC—prostate cancer	2.84e-05	0.000168	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EGF—prostate cancer	2.83e-05	0.000168	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IRS1—prostate cancer	2.83e-05	0.000168	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EGF—prostate cancer	2.81e-05	0.000166	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IRS1—prostate cancer	2.81e-05	0.000166	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—GSK3B—prostate cancer	2.76e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—GSK3B—prostate cancer	2.75e-05	0.000163	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—GSK3B—prostate cancer	2.72e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—INS—prostate cancer	2.72e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—INS—prostate cancer	2.71e-05	0.000161	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—INS—prostate cancer	2.69e-05	0.000159	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CREBBP—prostate cancer	2.67e-05	0.000158	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CREBBP—prostate cancer	2.66e-05	0.000158	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IGF1—prostate cancer	2.63e-05	0.000156	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CREBBP—prostate cancer	2.63e-05	0.000156	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CB—prostate cancer	2.63e-05	0.000156	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IGF1—prostate cancer	2.62e-05	0.000156	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—EGFR—prostate cancer	2.62e-05	0.000155	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—EGFR—prostate cancer	2.61e-05	0.000155	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PTGS2—prostate cancer	2.6e-05	0.000154	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IGF1—prostate cancer	2.6e-05	0.000154	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—EGFR—prostate cancer	2.59e-05	0.000153	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	2.54e-05	0.000151	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	2.54e-05	0.000151	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	2.53e-05	0.00015	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	2.52e-05	0.00015	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	2.51e-05	0.000149	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	2.5e-05	0.000149	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	2.5e-05	0.000148	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	2.5e-05	0.000148	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	2.5e-05	0.000148	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	2.49e-05	0.000148	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—KRAS—prostate cancer	2.48e-05	0.000147	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	2.47e-05	0.000147	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	2.47e-05	0.000146	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—KRAS—prostate cancer	2.47e-05	0.000146	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—KRAS—prostate cancer	2.44e-05	0.000145	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—FGF2—prostate cancer	2.42e-05	0.000144	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—FGF2—prostate cancer	2.41e-05	0.000143	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—FGF2—prostate cancer	2.39e-05	0.000142	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NOS3—prostate cancer	2.39e-05	0.000142	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NOS3—prostate cancer	2.38e-05	0.000141	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NOS3—prostate cancer	2.36e-05	0.00014	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—JAK2—prostate cancer	2.32e-05	0.000138	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—JAK2—prostate cancer	2.31e-05	0.000137	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—JAK2—prostate cancer	2.29e-05	0.000136	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	2.27e-05	0.000135	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PTEN—prostate cancer	2.27e-05	0.000135	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	2.27e-05	0.000134	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MDM2—prostate cancer	2.26e-05	0.000134	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MDM2—prostate cancer	2.26e-05	0.000134	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	2.24e-05	0.000133	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MDM2—prostate cancer	2.24e-05	0.000133	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ERBB2—prostate cancer	2.23e-05	0.000132	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ERBB2—prostate cancer	2.23e-05	0.000132	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ERBB2—prostate cancer	2.2e-05	0.000131	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	2.2e-05	0.000131	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	2.2e-05	0.00013	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	2.18e-05	0.000129	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—EP300—prostate cancer	2.16e-05	0.000128	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CXCL8—prostate cancer	2.12e-05	0.000126	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CXCL8—prostate cancer	2.11e-05	0.000125	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CXCL8—prostate cancer	2.09e-05	0.000124	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	2.07e-05	0.000123	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	2.06e-05	0.000122	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	2.05e-05	0.000121	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	2.04e-05	0.000121	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	2.04e-05	0.000121	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CASP3—prostate cancer	2.03e-05	0.00012	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL2—prostate cancer	2.02e-05	0.00012	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CASP3—prostate cancer	2.02e-05	0.00012	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	2.02e-05	0.00012	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL2—prostate cancer	2.02e-05	0.00012	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—IL6—prostate cancer	2.01e-05	0.000119	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—IL6—prostate cancer	2.01e-05	0.000119	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CASP3—prostate cancer	2e-05	0.000119	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL2—prostate cancer	2e-05	0.000119	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—IL6—prostate cancer	1.99e-05	0.000118	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CCND1—prostate cancer	1.97e-05	0.000117	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CCND1—prostate cancer	1.97e-05	0.000117	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	1.95e-05	0.000116	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	1.95e-05	0.000116	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CCND1—prostate cancer	1.95e-05	0.000116	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	1.93e-05	0.000114	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MMP9—prostate cancer	1.92e-05	0.000114	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MMP9—prostate cancer	1.91e-05	0.000113	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	1.91e-05	0.000113	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.9e-05	0.000113	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	1.9e-05	0.000113	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PTEN—prostate cancer	1.9e-05	0.000113	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.89e-05	0.000112	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.88e-05	0.000112	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.88e-05	0.000112	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—AKT1—prostate cancer	1.86e-05	0.00011	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—AKT1—prostate cancer	1.85e-05	0.00011	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—AKT1—prostate cancer	1.83e-05	0.000109	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EP300—prostate cancer	1.82e-05	0.000108	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EP300—prostate cancer	1.81e-05	0.000107	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EP300—prostate cancer	1.79e-05	0.000106	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SRC—prostate cancer	1.77e-05	0.000105	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SRC—prostate cancer	1.76e-05	0.000104	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SRC—prostate cancer	1.74e-05	0.000103	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—VEGFA—prostate cancer	1.72e-05	0.000102	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—VEGFA—prostate cancer	1.71e-05	0.000102	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—STAT3—prostate cancer	1.7e-05	0.000101	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—VEGFA—prostate cancer	1.7e-05	0.000101	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—STAT3—prostate cancer	1.7e-05	0.000101	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—STAT3—prostate cancer	1.68e-05	9.97e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3CA—prostate cancer	1.6e-05	9.5e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MYC—prostate cancer	1.58e-05	9.39e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TGFB1—prostate cancer	1.58e-05	9.37e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MYC—prostate cancer	1.58e-05	9.36e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TGFB1—prostate cancer	1.57e-05	9.34e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MYC—prostate cancer	1.56e-05	9.27e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TGFB1—prostate cancer	1.56e-05	9.25e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EGFR—prostate cancer	1.55e-05	9.18e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EGFR—prostate cancer	1.54e-05	9.15e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EGFR—prostate cancer	1.53e-05	9.07e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—KRAS—prostate cancer	1.46e-05	8.68e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—KRAS—prostate cancer	1.46e-05	8.65e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—KRAS—prostate cancer	1.44e-05	8.56e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	1.34e-05	7.97e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	1.34e-05	7.94e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	1.33e-05	7.87e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—AKT1—prostate cancer	1.31e-05	7.76e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TP53—prostate cancer	1.3e-05	7.71e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TP53—prostate cancer	1.3e-05	7.69e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TP53—prostate cancer	1.28e-05	7.61e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL6—prostate cancer	1.19e-05	7.06e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL6—prostate cancer	1.19e-05	7.04e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL6—prostate cancer	1.17e-05	6.97e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AKT1—prostate cancer	1.1e-05	6.51e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AKT1—prostate cancer	1.09e-05	6.49e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AKT1—prostate cancer	1.08e-05	6.43e-05	CbGpPWpGaD
